EP2968609A4 - Vectors and methods to treat ischemia - Google Patents

Vectors and methods to treat ischemia

Info

Publication number
EP2968609A4
EP2968609A4 EP14765183.0A EP14765183A EP2968609A4 EP 2968609 A4 EP2968609 A4 EP 2968609A4 EP 14765183 A EP14765183 A EP 14765183A EP 2968609 A4 EP2968609 A4 EP 2968609A4
Authority
EP
European Patent Office
Prior art keywords
vectors
methods
treat ischemia
ischemia
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP14765183.0A
Other languages
German (de)
French (fr)
Other versions
EP2968609A2 (en
Inventor
Jan Nolta
Karen Pepper
Fernando Fierro
Gerhard Bauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/844,138 external-priority patent/US20140065110A1/en
Application filed by University of California filed Critical University of California
Publication of EP2968609A2 publication Critical patent/EP2968609A2/en
Publication of EP2968609A4 publication Critical patent/EP2968609A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
EP14765183.0A 2013-03-15 2014-03-14 Vectors and methods to treat ischemia Ceased EP2968609A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/844,138 US20140065110A1 (en) 2012-08-31 2013-03-15 Genetically modified msc and therapeutic methods
PCT/US2013/057721 WO2014036524A2 (en) 2012-08-31 2013-08-30 Genetically modified msc and therapeutic methods
PCT/US2014/029386 WO2014144815A2 (en) 2013-03-15 2014-03-14 Vectors and methods to treat ischemia

Publications (2)

Publication Number Publication Date
EP2968609A2 EP2968609A2 (en) 2016-01-20
EP2968609A4 true EP2968609A4 (en) 2016-11-30

Family

ID=51538378

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14765183.0A Ceased EP2968609A4 (en) 2013-03-15 2014-03-14 Vectors and methods to treat ischemia

Country Status (3)

Country Link
EP (1) EP2968609A4 (en)
AU (2) AU2014228526A1 (en)
WO (1) WO2014144815A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US7297536B2 (en) * 2003-01-23 2007-11-20 Wisconsin Alumni Research Foundation Inducible protein expression system
WO2007047963A2 (en) * 2005-10-20 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of bone-marrow derived stem cells to treat ischemia
US9096827B2 (en) * 2008-09-02 2015-08-04 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
EP2425001A4 (en) * 2009-04-30 2012-11-14 Univ California Combination anti-hiv vectors, targeting vectors, and methods of use
EP2580331A4 (en) * 2010-06-14 2013-11-27 Univ Iowa State Res Found Inc Nuclease activity of tal effector and foki fusion protein

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AFRAMIAN D J ET AL: "Using HSV-thymidine kinase for safety in an allogeneic salivary graft cell line", TISSUE ENGINEERING, vol. 7, no. 4, 1 August 2001 (2001-08-01), LARCHMONT, NY, US, pages 405 - 413, XP002761134, ISSN: 1076-3279 *
AKESON ANN L ET AL: "Temporal and spatial regulation of VEGF-A controls vascular patterning in the embryonic lung.", DEVELOPMENTAL BIOLOGY, vol. 264, no. 2, 15 December 2003 (2003-12-15), pages 443 - 455, XP002762759, ISSN: 0012-1606 *
CHANG DAVID S ET AL: "Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 7, no. 1, January 2003 (2003-01-01), pages 44 - 51, XP002717242, ISSN: 1525-0016 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 2010 (2010-05-01), FANG YU XIANG ET AL: "Development of Chimeric Gene Regulators for Cancer-specific Gene Therapy with both Transcriptional and Translational Targeting", XP002762768, Database accession no. PREV201000282618 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 1996 (1996-09-01), ZHOU A ET AL: "[Molecular bypass, the application of VEGF to gene therapy of limb ischemia].", XP002762757, Database accession no. NLM9275547 *
FIERRO FERNANDO A ET AL: "Effects on Proliferation and Differentiation of Multipotent Bone Marrow Stromal Cells Engineered to Express Growth Factors for Combined Cell and Gene Therapy", STEM CELLS (MIAMISBURG), vol. 29, no. 11, November 2011 (2011-11-01), pages 1727 - 1737, XP002717241 *
MOLECULAR BIOTECHNOLOGY, vol. 45, no. 1, May 2010 (2010-05-01), pages 71 - 81, ISSN: 1073-6085, DOI: 10.1007/S12033-010-9244-Y *
NAIDOO JERUSHA ET AL: "Gene regulation systems for gene therapy applications in the central nervous system.", NEUROLOGY RESEARCH INTERNATIONAL, vol. 2012, 595410, 2012, pages 1 - 10, XP002762760, ISSN: 2090-1860, DOI: 10.1155/2012/595410 *

Also Published As

Publication number Publication date
WO2014144815A2 (en) 2014-09-18
AU2014228526A1 (en) 2015-11-05
AU2019201858A1 (en) 2019-04-11
EP2968609A2 (en) 2016-01-20
WO2014144815A3 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
IL291723A (en) Methods and devices for skin tightening
HK1218506A1 (en) Methods of treating melanoma
EP2981623A4 (en) Systems and methods to assess microbiomes and treatments thereof
EP2996630A4 (en) Catheter-based apparatuses and methods
PL2968100T3 (en) Combination of alkylamidothiazoles and preservatives
ZA201506534B (en) Method of treating hair
ZA201507771B (en) Compounds and methods to isolate gold
HK1211836A1 (en) Neuroprotective effect of carotenoids in brain
EP2956171A4 (en) Methods to protect against and treat multiple sclerosis
HK1215164A1 (en) Treatment methods
EP2987086A4 (en) Secure computing
GB201514996D0 (en) Rebreather system and components
EP2941536A4 (en) Analyzying sand stabilization treatments
HK1217633A1 (en) Lyophilization process
GB201304872D0 (en) Treatment
GB201305366D0 (en) Improved suitcase
EP2968609A4 (en) Vectors and methods to treat ischemia
GB201310441D0 (en) Suitcase/sunlounger/campbed
GB201307310D0 (en) Treatment
GB201300324D0 (en) Improvements to letter-plates
GB201316725D0 (en) Device to prevent loss of belongings
GB2522975B (en) Improvements to handle assemblies
GB201309138D0 (en) Methods and apparatuses relating to injection-moulded objects
GB2519994B (en) Assemblies and methods
GB2511577B (en) Carrying structure

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151013

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/867 20060101AFI20161017BHEP

Ipc: A61K 48/00 20060101ALI20161017BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161031

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20161024BHEP

Ipc: C12N 15/867 20060101AFI20161024BHEP

17Q First examination report despatched

Effective date: 20170906

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20190124